References

Radiotherapy and immunotherapy: a beneficial liaison?

10.1038/nrclinonc.2016.211 · 2017 · External reference

Antibody therapy of cancer

10.1038/nrc3236 · 2012 · External reference

Antibody targeted drugs as cancer therapeutics

10.1038/nrd1957 · 2006 · External reference

The increasingly human and profitable monoclonal antibody market

10.1016/j.tibtech.2018.05.014 · 2019 · External reference

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

10.1001/jama.2020.4783 · 2020 · External reference

Monoclonal antibody as a potential anti-COVID-19

10.1016/j.biopha.2020.110337 · 2020 · External reference

Unresolved reference

External reference

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

10.1086/524891 · 2008 · External reference

Where are we with monoclonal antibodies for multidrug-resistant infections?

10.1016/j.drudis.2019.03.002 · 2019 · External reference

Antibodies: an alternative for antibiotics?

10.1093/ps/84.4.660 · 2005 · External reference

Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration “Animal Rule”

2015 · External reference

Animal‐to‐human dose translation of obiltoxaximab for treatment of inhalational anthrax under the US FDA Animal Rule

10.1111/cts.12433 · 2017 · External reference

FDA approves antitoxin antibody

10.1038/nrd.2016.257 · 2016 · External reference

Monoclonal Antibodies as an Antibacterial Approach against Bacterial Pathogens

10.3390/antibiotics9040155 · 2020 · External reference

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

10.1056/nejmoa1910993 · 2019 · External reference

Monoclonal Antibody Approved to Treat Ebola

10.1097/01.naj.0000742484.81331.b2 · 2021 · External reference

The Ebola epidemic in West Africa: challenges, opportunities, and policy priority areas

10.1016/j.outlook.2014.12.013 · 2015 · External reference

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

10.1126/science.abd0831 · 2020 · External reference

Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus

10.1086/599794 · 2009 · External reference

Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker

10.1016/s0021-9258(19)74471-8 · 1993 · External reference

Healthy humans can be a source of antibodies countering COVID-19

10.1080/21655979.2022.2076390 · 2022 · External reference

Combination approaches to combat multidrug-resistant bacteria

10.1016/j.tibtech.2012.12.006 · 2013 · External reference

Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics

10.1038/s41435-019-0065-0 · 2019 · External reference

Yersinia pestis—etiologic agent of plague

10.1128/cmr.10.1.35 · 1997 · External reference

Human plague: An old scourge that needs new answers

10.1371/journal.pntd.0008251 · 2020 · External reference

Trends of Human Plague, Madagascar, 1998–2016

10.3201/eid2502.171974 · 2019 · External reference

Epidemiological characteristics of an urban plague epidemic in Madagascar, August-November, 2017: an outbreak report

10.1016/s1473-3099(18)30730-8 · 2019 · External reference

Pneumonic plague outbreak, Northern Madagascar, 2011

10.3201/eid2101.131828 · 2015 · External reference

Resistance of Yersinia pestis to antimicrobial agents

10.1128/aac.00306-06 · 2006 · External reference

Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat

10.1016/j.ijantimicag.2017.09.015 · 2018 · External reference

Biological agents: weapons of warfare and bioterrorism

10.2165/00066982-200106040-00013 · 2001 · External reference

Pneumonic plague: the darker side of Yersinia pestis

10.1016/j.tim.2015.11.008 · 2016 · External reference

The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague

10.1128/iai.00950-08 · 2009 · External reference

Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis

10.1128/iai.70.3.1453-1460.2002 · 2002 · External reference

Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis

10.4269/ajtmh.1997.56.471 · 1997 · External reference

Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis

10.1128/iai.71.4.2234-2238.2003 · 2003 · External reference

Administration of antibody to the lung protects mice against pneumonic plague

10.1128/iai.74.5.3068-3070.2006 · 2006 · External reference

Treatment of plague: promising alternatives to antibiotics

10.1099/jmm.0.46697-0 · 2006 · External reference

Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model

10.1371/journal.pone.0013047 · 2010 · External reference

Rapid and sensitive detection of Yersinia pestis by lateral-flow assay in simulated clinical samples

2018 · External reference

Development of Anti-Yersinia pestis Human Antibodies with Features Required for Diagnostic and Therapeutic Applications

10.2147/itt.s267077 · 2020 · External reference

Construction, characterization and crystal structure of a fluorescent single-chain Fv chimera

10.1093/protein/gzaa029 · 2021 · External reference

Beyond natural antibodies: the power of in vitro display technologies

10.1038/nbt.1791 · 2011 · External reference

10.1016/b978-012164730-8/50060-5

10.1016/b978-012164730-8/50060-5 · 2006 · External reference

Phage display

10.1021/cr960065d · 1997 · External reference

[25] Yeast surface display for directed evolution of protein expression, affinity, and stability

10.1016/s0076-6879(00)28410-3 · 2000 · External reference

Hybridoma technology for production of monoclonal antibodies

2010 · External reference

Hybridoma technologies for antibody production

10.2217/imt.11.4 · 2011 · External reference

Selection and characterization of FcεRI phospho-ITAM specific antibodies

10.1080/19420862.2019.1632113 · 2019 · External reference

Unresolved reference

External reference

Development of phage-based single chain Fv antibody reagents for detection of Yersinia pestis

10.1371/journal.pone.0027756 · 2011 · External reference

Applications of Yeast Surface Display for Protein Engineering

10.1007/978-1-4939-2748-7_8 · 2015 · External reference

Biophysical properties of the clinical-stage antibody landscape

10.1073/pnas.1616408114 · 2017 · External reference

Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies

10.1080/02648725.2007.10648095 · 2007 · External reference

Analysis of aggregates of human immunoglobulin G using size-exclusion chromatography, static and dynamic light scattering

10.1016/s0021-9673(03)00433-3 · 2003 · External reference

Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis

10.1006/mpat.2002.0498 · 2002 · External reference

Roles of V antigen in promoting virulence in Yersiniae

1987 · External reference

Novel plasmids and resistance phenotypes in Yersinia pestis: unique plasmid inventory of strain Java 9 mediates high levels of arsenic resistance

10.1371/journal.pone.0032911 · 2012 · External reference

F1-negative natural Y. pestis strains

10.1007/0-306-48416-1_76 · 2003 · External reference

An unusual strain of Pasteurella pestis isolated from a fatal human case of plague

1960 · External reference

Virulent non-capsulate Yersinia pestis variants constructed by insertion mutagenesis

10.1099/00222615-42-4-264 · 1995 · External reference

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis

10.1093/clinids/21.supplement_2.s178 · 1995 · External reference

Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops)

1996 · External reference

Pathology and Pathogenesis of Yersinia pestis

10.1007/978-94-024-0890-4_7 · 2016 · External reference

Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the Yersinia pestis Plague rF1V Vaccine

10.3389/fimmu.2021.726416 · 2021 · External reference

Live attenuated vaccines and layered defense strategies to combat infections caused by nonencapsulated Yersinia pestis

10.3389/fbrio.2023.1240698 · 2023 · External reference

Recombinant renewable polyclonal antibodies

10.4161/19420862.2015.989047 · 2015 · External reference

Unresolved reference

2020 · External reference

Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague

10.1016/s0264-410x(02)00119-6 · 2002 · External reference

Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona

10.4269/ajtmh.1994.51.109 · 1994 · External reference

A strategy to verify the absence of the pgm locus in Yersinia pestis strain candidates for select agent exemption

10.1016/j.mimet.2009.02.013 · 2009 · External reference

Functional assays to screen and select monoclonal antibodies that target Yersinia pestis

10.1080/21645515.2023.2216085 · 2023 · External reference

A Yersinia pestis tat mutant is attenuated in bubonic and small-aerosol pneumonic challenge models of infection but not as attenuated by intranasal challenge

10.1371/journal.pone.0104524 · 2014 · External reference

A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice

10.1111/j.1574-6968.2012.02583.x · 2012 · External reference